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cost of symptomatic drugs (−22% for R; −34% for R + A) in
SLIT patients. CONCLUSIONS: Use of symptomatic drugs is an
important indicator of effective allergy control: other studies
have shown SLIT can reduce the use of drugs for asthma and
rhinitis, but this is the ﬁrst time this outcome is demonstrated in
a routine care population, in the medical practice environment
of an observational study, and yet at the ﬁrst year of treatment.
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OBJECTIVES: Exacerbations—consequence of poor control of
asthma—are the main component of high cost of this disease.
The aim of the study was the cost comparison of managing
asthma exacerbations with two types of treatment: stable dosing
of SFC and AMD of FBC. METHOD: The analysis was per-
formed from health-care payer perspective, based on Polish data
on health-care resource utilisation and unit cost obtained from
COAX study, estimating cost of asthma exacerbation managed
in primary and secondary care in Poland. Data on incidence of
asthma exacerbations in two types of treatment were derived
from 1-year CONCEPT Trial—the only available double blind,
double dummy, randomized study in adults with persistent
asthma, comparing stable dosing SFC with AMD of FBC.
RESULTS: Study population was 688 patients (344 in each treat-
ment arm). 11.3% patients on stable dosing of SFC experienced
an asthma exacerbation compared with 17.7% patients receiv-
ing AMD of FBC. There were 48% fewer exacerbations in the
stable dosing SFC group than in AMD with FBC (50 vs. 96 exac-
erbations respectively). The incidence of asthma exacerbations
requiring oral steroids or an emergency room visit/hospitaliza-
tion was 47% lower for the stable dosing SFC group than for
AMD with FBC (adjusted annual mean rate, 0.18 vs 0.33; P =
0.008). The total annual direct health care costs of managing
exacerbations for the stable dosing SFC group was PLN 19.833
compared with PLN 34.936 for the AMD with FBC group. Dif-
ference in annual costs of managing exacerbations was PLN
15.103 (EUR 1 = PLN 4,02; year 2005). CONCLUSION: Stable
dose treatment with salmeterol/ﬂuticasone combined product of
adult patients with persistent asthma is more effective than the
adjustable maintenance dosing with formoterol/budesonide com-
bined product and reduces the cost of exacerbations manage-
ment by 43%.
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OBJECTIVES: To perform cost–effectiveness analysis of combos
budesonide/formoterol in different dosing regimes and ﬁxed
dosing salmoterol/ﬂuticasone in bronchial asthma (BA) treat-
ment in Russia. METHODS: Modeling study based on the
results of international randomized double blind study of 6 coun-
tries outpatient practice published by R. Albers, et al.* Three
group patients with BA were assessed: group 1 (n = 219)—
adjustable maintenance dosing budesonide/formoterol 160/4,5
micrograms, 1st month—2 inhalations twice a day and next 6
month—on average 3,4 inhalations a day; group 2 (n = 215)—
ﬁxed dosing the same product, 2 inhalations twice a day and
group 3 (n = 224)—ﬁxed dosing salmeterol/ﬂuticasone 50/250
micrograms, 1 inhalation twice a day. Direct medical costs (DC)
were taken into account from the health care system point of
view and consisted of expenditures on products usage and treat-
ment of complications. Effectiveness (E) was the average percent
of pts with a week of well-controlled asthma based on clinical
study results. There was a signiﬁcant positive dynamics in all
groups accordingly: E1 = 65%, E2 = 50% and E3 = 55%.
RESULTS: Direct cost (DC) for each group were: DC1 = 364
EUR, DC2 = 417 EUR and DC3 = 420 EUR respectively. Cost—
effectiveness ratio (CER): CER1 = 5.58, CER2 = 8.34 and CER3
= 7.63 EUR per percent of pts with a week of well-controlled
asthma respectively as well. CONCLUSION: adjustable mainte-
nance dosing budesonide/formoterol is the best choose to treat
pts with BA based on cost-effectiveness analysis results.
*-R. Albers, et al. Current medical research and opinion.
2004:20:225–40.
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OBJECTIVES: Fractional exhaled nitric oxide (FENO) is a
measure for the airway inﬂammation underlying asthma, which
can be used for both diagnosis and monitoring the effect of anti-
inﬂammatory treatment. The objective of this study was to assess
the cost-effectiveness of NIOX MINO®, a portable non-invasive
FENO monitor, in asthma diagnosis and management.
METHODS: Two decision trees were constructed that capture
the different alternatives and consequences in asthma diagnosis
and management. Reﬂecting available clinical data on diagnostic
precision, NIOX MINO was compared against standard diag-
nostics, including spirometry, reversibility testing, bron-
choprovocation and sputum eosinophil count. The impact of
asthma management with NIOX MINO on inhaled steroid use,
exacerbations and hospitalisations was compared against stan-
dard guidelines (spirometry) over a 1-year timeframe. A German
payer perspective was chosen, focusing on direct medical costs
taken from published sources in 2006. Effectiveness was mea-
sured in quality-adjusted life-years (QALYs). RESULTS: Asthma
diagnosis based on NIOX MINO results in a cost of €12 per
patient, including the cost of false diagnoses, compared to €20
for standard diagnostics. If NIOX MINO is conducted in addi-
tion to standard tests, the incremental cost would be up to €7
per patient. Asthma management with NIOX MINO instead of
standard guidelines is a dominant strategy. In mild to severe
patients, it results in cost-savings of €140 per patient and year
and 0.06 QALYs gained. In a more severe population, manage-
ment with NIOX MINO would save costs of €260 per patient
and lead to 0.004 QALYs gained. CONCLUSIONS: Asthma
diagnosis based on NIOX MINO alone is less costly and more
accurate than standard diagnostic methods, while the addition
of NIOX MINO to spirometry increases costs marginally. The
use of NIOX MINO in treatment decisions is less costly than
asthma management based on standard guidelines, while pro-
viding the same health beneﬁts.
